Palvella Therapeutics, Inc.
151.34USD
-0.9400 (-0.62%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -21 | -15 | -11 | -10 | -9 | -8 | -4 | -5 |
| Net Income | -22 | -16 | -13 | -11 | -9 | -8 | -4 | -7 |
| EPS (Diluted) | $-1.52 | $-1.20 | $-1.08 | $-1.03 | $-0.86 | $-0.74 | $0.12 | $-3.94 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)